Celyad Oncology's revenue for the
six
months ended in Dec. 2025 was $0.01 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02 Mil.
Celyad Oncology's Revenue per Share for the
six
months ended in Dec. 2025 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
During the past 13 years, Celyad Oncology's highest 3-Year average Revenue per Share Growth Rate was 155.70% per year. The lowest was 76.50% per year. And the median was 116.10% per year.
Celyad Oncology (OTCPK:CLYYF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Celyad Oncology Revenue Related Terms
Celyad Oncology Revenue Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Revenue distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Revenue of $0.02 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Celyad Oncology and its competitors.
Is Celyad Oncology's Revenue too high?
Celyad Oncology's current Revenue is $0.02 Mil. Overall, Celyad Oncology has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Revenue compare to VRTX and REGN?
Celyad Oncology's Revenue of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current Revenue is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Celyad Oncology (CLYYF) has a current Revenue of $0.02 Mil. The stock's GF Value™ is $0.47, compared to a current price of $0.25 — trading 46.8% below its estimated fair value. The current Revenue is $0.02 Mil. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Revenue is $0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued.
The current stock price of $0.25 is trading 46.8% below its estimated GF Value™ of $0.47.
Key valuation signals for CLYYF:
Revenue: $0.02 Mil
GF Value™: $0.47 vs. price of $0.25 (46.8% below fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score
Get the complete analysis for CLYYF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
